# Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

> **NCT02278055** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Pain

## Interventions

- **DRUG:** Radium-223

## Key facts

- **NCT ID:** NCT02278055
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-08
- **Primary completion:** 2022-02-02
- **Final completion:** 2022-02-02
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02278055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02278055, "Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02278055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*